723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning

723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning

Bibliographic Details
Main Authors: Lawrence G Lum, Martin Gutierrez, Sunil Patel, Michele Donato, Jee Hyun Park, Tania Felizardo, Daniel H Fowler, Morgan Finlay, Ronit Reich-Slotky, Research Nurse Coordinator
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items